OMMAYA ARTIFICIAL ORGAN FOR ISLET TRANSPLANTATION

拟议的研究旨在建立一个可行性， 含有胰岛细胞的用于治疗 胰岛素依赖型糖尿病该装置是一个直接应用的 脊髓液流动驱动的人造器官由私家侦探发明。（仅限 专利号5，222，982）。体外和体内初步实验 （犬模型）表明异种移植胰岛细胞是免疫保护的 生活在脑脊液中，脑脊液葡萄糖跟随血糖，脑脊液中有胰岛 延迟时间小于25分钟的胰岛素释放和糖尿病犬 在短时间内显示血清葡萄糖和胰岛素需求减少， 长期观察这些数据载于我们提案的正文。我们 寻求延长和完成这些观察， 用大量的胰岛治疗，并确认免疫保护 包括缺乏对蛋白质的显著宿主致敏性 与异种胰岛有关。这项工作将继续进行， 在使用CRADA之前，NIDDK/NIH的Illani Atwater博士和J. NCRR/NIH的Bacher。

The proposed research seeks to establish the feasibility of a macroencapsulation device containing islet cells for the treatment of insulin dependent diabetes. The device is a direct application of the spinal fluid flow driven artificial organ invented by the P.I. (U.S. Patent No. 5,222,982). Preliminary experiments in vitro and in vivo (canine model) indicate that xenograft islet cells are immune protected while living in CSF, CSF glucose follows serum glucose, islets in CSF release insulin with lag times less than 25 minutes and diabetic dogs display decrease of serum glucose and insulin requirements under short- term observation. These data are presented in the body of our proposal. We seek to extend and complete these observations for longer periods of treatment with larger numbers of islets and confirm the immune protection including the lack of significant host sensitization to proteins associated with the xenogenic islets. The work will be carried on as before using a CRADA with Dr. Illani Atwater at NIDDK/NIH and with Dr. J. Bacher at NCRR/NIH.